Skip to main content
SpringerLink
Log in

Autoimmune Dermatoses

  • Chapter
  • First Online:
Practical Immunodermatology

  • 1134 Accesses

Abstract

Lichen sclerosus (LS) is a dermatosis that has a predilection for the anogenital skin and is significantly more common in females than in males. The etiology remains unclear, and while there is an association with other autoimmune disorders in females, this is not the case in males. It is an important condition to diagnose and treat early as it can lead to scarring without timely treatment but this can be halted with the application of an ultrapotent topical steroid. The classic lesion is a white sclerotic plaque, and these occur on the anogenital skin and at extragenital sites in a minority of patients. There is a small risk of malignancy of the genital lesions and careful follow-up of these patients is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

Pemphigus

  1. Amagai M. Pemphigus: autoimmunity to epidermal cell adhesion molecules. Adv Dermatol. 1996;11:319–52.

    CAS  PubMed  Google Scholar 

  2. Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity. 2012;45(1):55–70.

    Article  CAS  PubMed  Google Scholar 

  3. Ahmed AR, et al. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci. 1990;87:7658–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Niizeki H, et al. HLA-DQA1, -DQB1 and -DRB1 genotyping in Japanese pemphigus vulgaris patients by the PCR-RFLP method. Tissue Antigens. 1994;44:248–51.

    Article  CAS  PubMed  Google Scholar 

  5. Veldman C, et al. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol. 2003;170:635–42.

    Article  CAS  PubMed  Google Scholar 

  6. Hertl M, Veldman C. Pemphigus–paradigm of autoantibody-mediated autoimmunity. Skin Pharmacol Appl Skin Physiol. 2001;14:408–18.

    Article  CAS  PubMed  Google Scholar 

  7. Stanley JR. Autoantibodies against adhesion molecules and structures in blistering skin diseases. J Exp Med. 1995;181:1–4.

    Article  CAS  PubMed  Google Scholar 

  8. Daneshpazhooh M, et al. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vul garis: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol. 2007;21(10):1319–24.

    Article  CAS  PubMed  Google Scholar 

  9. Shapiro L, et al. Structural basis of cell-cell adhesion by cadherins. Nature. 1995;374:327–37.

    Article  CAS  PubMed  Google Scholar 

  10. Pan M, Liu X, Zheng J. The pathogenic role of autoantibodies in pemphigus vulgaris. Clin Exp Dermatol. 2011;36(7):703–7.

    Article  CAS  PubMed  Google Scholar 

  11. Anhalt GJ, et al. Paraneoplastic pemphigus an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35.

    Article  CAS  PubMed  Google Scholar 

  12. Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc. 2004;9:29–33.

    Article  Google Scholar 

  13. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16:393–7.

    Article  CAS  PubMed  Google Scholar 

  14. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29(4):455–7.

    Article  PubMed  Google Scholar 

  15. Jablonska S, et al. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 1975;14:353–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol. 2014;70(4):780–7.

    Article  PubMed  Google Scholar 

  17. Virendra N, et al. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48:162–9.

    Article  Google Scholar 

  18. Tsuruta D, Ishii N, Hashimoto T. Diagnosis and treatment of pemphigus. Immunotherapy. 2012;4:735–45.

    Article  CAS  PubMed  Google Scholar 

  19. Ferguson CD, Taybos GM. Diagnosis and treatment of pemphigus. Quintessence Int. 1985;16:473–6.

    CAS  PubMed  Google Scholar 

  20. Enrique Acosta Gio A. Immunofluorescence in the diagnosis and treatment of pemphigus vulgaris. Pract Odontol. 1986;7:6–8.

    CAS  PubMed  Google Scholar 

  21. Ruocco E, Brunetti G, Del Vecchio M, Ruocco V. The practical use of cytology for diagnosis in dermatology. J Eur Acad Dermatol Venereol. 2011;25:125–9.

    Article  CAS  PubMed  Google Scholar 

  22. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147:261–5.

    Article  CAS  PubMed  Google Scholar 

  23. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–14.

    Article  CAS  PubMed  Google Scholar 

  24. Joly P, Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S. [Pemphigus. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Societe Francaise de Dermatologie]. Ann Dermatol Venereol. 2011;138:252–8.

    Article  CAS  PubMed  Google Scholar 

  25. Yeh SW, Ahmed B, Sami N, Razzaque AA. Blistering disorders: diagnosis and treatment. Dermatol Ther. 2003;16:214–23.

    Article  CAS  PubMed  Google Scholar 

  26. Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012;45:111–8.

    Article  CAS  PubMed  Google Scholar 

  27. Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30:84–94.

    Article  PubMed  Google Scholar 

  28. Sinha AA, Hoffman MB, Janicke EC. Pemphigus vulgaris: approach to treatment. Eur J Dermatol. 2015;25(2):103–13.

    PubMed  Google Scholar 

Bullous Pemphigoid

  1. Korman N. Bullous pemphigoid. J Am Acad Dermatol. 1987;16(5 Pt 1):907–24.

    Article  CAS  PubMed  Google Scholar 

  2. Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–8.

    Article  CAS  PubMed  Google Scholar 

  3. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assaysin the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol. 2011;147:286–91.

    Article  PubMed  Google Scholar 

  4. Tsuji-Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16a domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci. 2005;37:145–9.

    Article  CAS  PubMed  Google Scholar 

  5. Liu Z, Diaz LA. Bullous pemphigoid: end of the century overview. J Dermatol. 2001;28(11):647–50.

    Article  CAS  PubMed  Google Scholar 

  6. Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors. Facts and controversies. Clin Dermatol. 2013;31:391–9.

    Article  PubMed  Google Scholar 

  7. Pomponi D, Di Zenzo G, Zennaro D, Calabresi V, Eming R, Zuzzi S, Bernardi ML, Scala E. Detection of IgG and IgE reactivity to BP180 using the ISAC microarray system. Br J Dermatol. 2013;168(6):1205–14.

    Article  CAS  PubMed  Google Scholar 

  8. Fania L, Caldarola G. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin Immunol. 2012;143(3):236–45.

    Article  CAS  PubMed  Google Scholar 

  9. Yayli S, Pelivani N. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. Br J Dermatol. 2011;165(5):1133–7.

    Article  CAS  PubMed  Google Scholar 

  10. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134(4):465–9.

    Article  CAS  PubMed  Google Scholar 

  11. Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30(1):60–5.

    Article  CAS  PubMed  Google Scholar 

  12. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.

    Article  CAS  PubMed  Google Scholar 

  13. Culton DA, Diaz LZ. Treatment of subepidermal immunobullous diseases. Clin Dermatol. 2012;30:95–102.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies. Clin Dermatol. 2010;28:337–43.

    Article  PubMed  Google Scholar 

Vitiligo

  1. Lotti T, Hanna D, Buggiani G, Urple M. The color of the skin: psyco-anthropologic implications. J Cosmet Dermatol. 2005;4(3):219–20.

    Article  CAS  PubMed  Google Scholar 

  2. Lee DY, Kim CR, Lee JH. Trichrome vitiligo in segmental type. Photodermatol Photoimmunol Photomed. 2011;27(2):111–2.

    Article  PubMed  Google Scholar 

  3. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73(3):149–56.

    Article  PubMed  Google Scholar 

  4. Chandrashekar L. Dermatoscopy of blue vitiligo. Clin Exp Dermatol. 2009;34(5):e125–6.

    Article  CAS  PubMed  Google Scholar 

  5. Huggins RH, Janusz CA, Schwartz RA. Vitiligo a sign of systemic disease. Indian J Dermatol Venereol Leprol. 2006;72:68–71.

    Article  PubMed  Google Scholar 

  6. Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lee BW, Schwartz RA, Hercogová J, Valle Y, Lotti TM. Vitiligo road map. Dermatol Ther. 2012;25 Suppl 1:S44–56.

    Article  PubMed  Google Scholar 

  8. Lotti TM, Hercogová J, Schwartz RA, et al. Treatments of vitiligo: what’s new at the horizon. Dermatol Ther. 2012;25 Suppl 1:S32–40.

    Article  PubMed  Google Scholar 

  9. Valle Y, Lotti TM, Hercogova J, Schwartz RA, Korobko IV. Multidisciplinary approach to R&D in vitiligo, a neglected skin disease. Dermatol Ther. 2012;25 Suppl 1:S1–9.

    Article  PubMed  Google Scholar 

  10. Lotti T, Hautmann G, Hercogovà J. Vitiligo: disease or symptom? From the confusion of the past to current doubts. In: Lotti T, Hercogovà J, editors. Vitiligo. Problems and solutions. New York/Basel: Marcel Dekker, Inc.; 2004. p. 1–14.

    Google Scholar 

  11. Hercogová J, Schwartz RA, Lotti TM. Classification of vitiligo: a challenging endeavor. Dermatol Ther. 2012;25 Suppl 1:S10–6.

    Google Scholar 

  12. Pietrzak A, Bartosińska J, Hercogová J, et al. Metabolic syndrome in vitiligo. Dermatol Ther. 2012;25 Suppl 1:S41–43.

    Google Scholar 

  13. Sun X, Xu A, Wei X, et al. Genetic epidemiology of vitiligo: a study of 815 probands and their families fromsouth China. Int J Dermatol. 2006;45(10):1176–81.

    Article  CAS  PubMed  Google Scholar 

  14. Lotti T, D’Erme AM. Vitiligo as a systemic disease. Clin Dermatol. 2014;32(3):430–4.

    Article  PubMed  Google Scholar 

  15. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.

    Article  PubMed  Google Scholar 

  16. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16:208–14.

    Article  PubMed  Google Scholar 

  17. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiologyof vitiligo: multilocus recessivity cross-validated. Am J Hum Genet. 1994;55:981–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Prignano F, Pescitelli L, Ricceri F, et al. The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. Int J Dermatol. 2008;47(10):1060–2.

    Article  PubMed  Google Scholar 

  19. Abu Tahir M, Pramod K, Ansari SH, et al. Current remedies for vitiligo. Autoimmun Rev. 2010;9(7):516–20.

    Article  CAS  PubMed  Google Scholar 

  20. Jin Y, Ferrara T, Gowan K, et al. Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J Invest Dermatol. 2012;132(6):1730–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci. 2005;39(3):137–46. 73.

    Article  CAS  PubMed  Google Scholar 

  22. Liu JB, Li M, Chen H, et al. Association of vitiligo with HLAA2: a meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(2):205–13.

    Article  PubMed  Google Scholar 

  23. Majumder PA. Genetics and prevalence of vitiligo vulgaris. In: Hann SK, Nordlund J, editors. Vitiligo: a monograph on the basic and clinical science. Oxford: Blackwell Science Ltd; 2000.

    Google Scholar 

  24. Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun. 2008;10:244–57.

    Article  CAS  PubMed  Google Scholar 

  25. Birlea SA, Laberge GS, Procopciuc LM, et al. CTLA4 and generalized vitiligo: two genetic association studies and a meta-analysis of published data. Pigment Cell Melanoma Res. 2009;22:230–4.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Canton I, Akhtar S, Gavalas NG, et al. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun. 2005;6:584–7.

    Article  CAS  PubMed  Google Scholar 

  27. Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010;20(7):745–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Colucci R, Lotti F, Dragoni F, et al. High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients. Br J Dermatol. 2014;24.

    Google Scholar 

  29. Arunachalam M, Colucci R, Berti S, et al. Autoimmune signals in non-segmental vitiligo patients are associated with distinct clinical parameters and toxic exposures. J Eur Acad Dermatol Venereol. 2013;27(8):961–6.

    Article  CAS  PubMed  Google Scholar 

  30. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9:689–96.

    Article  CAS  PubMed  Google Scholar 

  31. Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol. 1989;7:136–45.

    Article  CAS  PubMed  Google Scholar 

  32. Cui J, Harning R, Henn M, Bystryn JC. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol. 1992;98:162–5.

    Article  CAS  PubMed  Google Scholar 

  33. Cui J, Arita Y, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Res. 1995;8:53–9.

    Article  CAS  PubMed  Google Scholar 

  34. Song YH, Connor E, Li Y, Zorovich B, et al. The role of tyrosinase in autoimmune vitiligo. Lancet. 1994;344:1049–52.

    Article  CAS  PubMed  Google Scholar 

  35. Baharav E, Merimski O, Shoenfeld Y, et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol. 1996;105:84–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Xie Z, Chen D, Jiao D, Bystryn JC. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol. 1999;135:417–22.

    Article  CAS  PubMed  Google Scholar 

  37. Okamoto T, Irie RF, Fujii S, Huang SK, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving activespecific immunotherapy. J Invest Dermatol. 1998;111:1034–9.

    Article  CAS  PubMed  Google Scholar 

  38. Kemp EH, Gawkrodger DJ, Watson PF, et al. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol. 1997;109:495–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol. 1998;139:798–805.

    Article  CAS  PubMed  Google Scholar 

  40. Hedstrand H, Ekwall O, Olsson MJ, et al. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem. 2001;276:35390–5.

    Article  CAS  PubMed  Google Scholar 

  41. Ruiz-Argüelles A, Brito GJ, Reyes-Izquierdo P, et al. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun. 2007;29(4):281–6.

    Article  PubMed  CAS  Google Scholar 

  42. Le Poole IC, van den Wijngaard RM, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996;148:1219–28.

    PubMed  PubMed Central  Google Scholar 

  43. Badri AM, Todd PM, Garioch JJ, et al. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol. 1993;170:149–55.

    Article  CAS  PubMed  Google Scholar 

  44. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998;188:1203–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Palermo B, Campanelli R, Garbelli S, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol. 2001;117:326–32.

    Article  CAS  PubMed  Google Scholar 

  46. Lang KS, Caroli CC, Muhm A, et al. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol. 2001;116(6):891–7.

    Article  CAS  PubMed  Google Scholar 

  47. Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19.

    Article  CAS  PubMed  Google Scholar 

  48. Colucci R, Lotti T, Moretti S. Vitiligo: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2012;13:1885–99.

    Article  CAS  PubMed  Google Scholar 

  49. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005;15:88–91.

    PubMed  Google Scholar 

  50. Gianfaldoni S, Zarrab Z, Lotti T. Phototherapy and Vitiligo Re-pigmentation: From PUVA to Micro-focused Phototherapy. Pigmentary Disorders. 2014;1:102. doi:10.4172/jpd.1000102.

    Google Scholar 

Alopecia Areata

  1. Qi S, Zhao Y, Zhang X, Li S, Cao H, Zhang X. Clinical features in primary cicatricial alopecia in Chinese patients. Indian J Derm Venereol Leprol. 2014;80(4):306–12.

    Article  Google Scholar 

  2. Olsen EA, Bergfeld WF, Cotsarelis G, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol. 2003;48(1):103–10.

    Article  PubMed  Google Scholar 

  3. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol. 1992;128:702.

    Article  CAS  PubMed  Google Scholar 

  4. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366:1515–25.

    Article  CAS  PubMed  Google Scholar 

  5. Picardi A, Pasquini P, Cattaruzza MS, et al. Psychosomatic factors in first-onset alopecia areata. Psychosomatics. 2003;44:374–81.

    Article  CAS  PubMed  Google Scholar 

  6. Huang KP, Mullangi S, Guo Y, et al. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149:789–94.

    Article  PubMed  Google Scholar 

  7. Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65(5):949–56.

    Article  PubMed  Google Scholar 

  8. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Petukhova L, Cabral RM, Mackay-Wiggan J, et al. The genetics of alopecia areata: What’s new and how will it help our patients? Dermatol Ther. 2011;24:326–36.

    Article  PubMed  Google Scholar 

  10. Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S16–22.

    Article  PubMed  Google Scholar 

  11. McElwee KJ, Gilhar A, Tobin DJ, Ramot Y, Sundberg JP, Nakamura M, Bertolini M, Inui S, Tokura Y, King Jr LE, Duque-Estrada B, Tosti A, Keren A, Itami S, Shoenfeld Y, Zlotogorski A, Paus R. What causes alopecia areata? Exp Dermatol. 2013;22(9):609–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bertolini M, Gilhar A, Paus R. Alopecia areata as a model for T cell-dependent autoimmune diseases[J]. Exp Dermatol. 2012;21(6):477–9.

    Article  PubMed  Google Scholar 

  13. Paus R, Ito N, Takigawa M, et al. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8:188–94.

    Article  PubMed  Google Scholar 

  14. Paus R, Arck P. Neuroendocrine perspectives in alopecia areata: does stress play a role? J Invest Dermatol. 2009;129:1324–6.

    Article  CAS  PubMed  Google Scholar 

  15. Hordinsky M, Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73–8.

    Article  PubMed  Google Scholar 

  16. Xiao FL, Yang S, Lin GS, et al. HLA haplotypic association with different phenotype of alopecia areata in Chinese Hans. J Dermatol Sci. 2007;45:206–9.

    Article  CAS  PubMed  Google Scholar 

  17. Entz P, Blaumeiser B, Betz RC, et al. Investigation of the HLA-DRB1 locus in alopecia areata. Eur J Dermatol. 2006;16:363–7.

    CAS  PubMed  Google Scholar 

  18. Goh C, Finkel M, Christos PJ, et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055–60.

    Article  CAS  PubMed  Google Scholar 

  19. Shuifeng Li, Xiaoting Zhang, Shiling Qi, Yanting Ye, Hui Cao, Yuqing Yang, Kevin J. McElwee, Xingqi Zhang. Allergy to dust mites may contribute to early onset and severity of alopecia areata. Clin Exp Dermatol. 2015; 40(2): 171-6.

    Google Scholar 

  20. Rebora A. Alopecia areata incognita. J Am Acad Dermatol. 2011;65(6):1228.

    Article  PubMed  Google Scholar 

  21. Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65:949–56.

    Article  PubMed  Google Scholar 

  22. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139:1555–9.

    Article  PubMed  Google Scholar 

  23. Dy LC, Whiting DA. Histopathology of alopecia areata, acute and chronic: Why is it important to the clinician? Dermatol Ther. 2011;24(3):369–74.

    Article  PubMed  Google Scholar 

  24. Elston DM, McCollough ML, Bergfeld WF, et al. Eosinophils in fibrous tracts and near hair bulbs: A helpful diagnostic feature of alopecia areata. J Am Acad Dermatol. 1997;37:101–6.

    Article  CAS  PubMed  Google Scholar 

  25. Bin Zhang, Ying Zhao, Zeming Cai, Sillani Caulloo, Kevin J McElwee, Mei Yu, Xiaohong Chen, Jian Yang, Wenna Chen, Xuhua Tang, Xingqi Zhang. Early stage alopecia areata is associated with inflammation in the upper dermis and damage to the hair follicle infundibulum. Aust J Derm. 2013;54(3):184–91.

    Google Scholar 

  26. Zhao Y, Zhang B, Caulloo S, Chen X, Yang L, Zhang X. Diffuse Alopecia Areata is associated with intense local inflammatory infiltration and CD8+ T cells in hair loss region and an increased IgE level. Indian J Derm Venereol Leprol. 2012;78(6):709–14.

    Article  Google Scholar 

  27. Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol. 2012;67(5):1040–8.

    Article  PubMed  Google Scholar 

  28. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata. Br J Dermatol. 2012;166(5):916–26.

    Article  CAS  PubMed  Google Scholar 

  29. Miteva M, Tosti A. Treatment options for alopecia: an update, looking to the future. Expert Opin Pharmacother. 2012;13(9):1271–81.

    Article  CAS  PubMed  Google Scholar 

  30. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg. 2009;28(1):15–8.

    Article  CAS  PubMed  Google Scholar 

  31. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. 1983;63(1):49–52.

    CAS  PubMed  Google Scholar 

  32. Sotiriadis D, Patsatsi A, Lazaridou E, et al. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol. 2007;32(1):48–51.

    CAS  PubMed  Google Scholar 

Lupus Erythematosus

  1. Gronhagen CM, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335–41.

    Article  CAS  PubMed  Google Scholar 

  2. Durosaro O, et al. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009;145(3):249–53.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Naleway AL, et al. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus. 2005;14(10):862–6.

    Article  CAS  PubMed  Google Scholar 

  4. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–18.

    Article  CAS  PubMed  Google Scholar 

  5. Nath SK, Kilpatrick J, Harley JB. Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol. 2004;16(6):794–800.

    Article  CAS  PubMed  Google Scholar 

  6. Arbuckle MR, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.

    Article  CAS  PubMed  Google Scholar 

  7. Li Y, et al. Overexpression of the growth arrest and DNA damage-induced 45alpha gene contributes to autoimmunity by promoting DNA demethylation in lupus T cells. Arthritis Rheum. 2010;62(5):1438–47.

    Article  CAS  PubMed  Google Scholar 

  8. Miot HA, Bartoli Miot LD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology. 2005;211(2):118–22.

    Article  PubMed  Google Scholar 

  9. Gallego H, et al. Report of an association between discoid lupus erythematosus and smoking. Cutis. 1999;63(4):231–4.

    CAS  PubMed  Google Scholar 

  10. Gronhagen CM, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case–control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296–305.

    Article  CAS  PubMed  Google Scholar 

  11. Corvetta A, et al. 5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. J Chromatogr. 1991;566(2):481–91.

    Article  CAS  PubMed  Google Scholar 

  12. Richardson B, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990;33(11):1665–73.

    Article  CAS  PubMed  Google Scholar 

  13. Hu N, et al. Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol. 2008;35(5):804–10.

    CAS  PubMed  Google Scholar 

  14. Amarilyo G, La Cava A. miRNA in systemic lupus erythematosus. Clin Immunol. 2012;144(1):26–31.

    Article  CAS  PubMed  Google Scholar 

  15. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–5.

    Article  CAS  PubMed  Google Scholar 

  16. Cardinali C, et al. The spectrum of cutaneous manifestations in lupus erythematosus--the Italian experience. Lupus. 2000;9(6):417–23.

    Article  CAS  PubMed  Google Scholar 

  17. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–81.

    Article  PubMed  Google Scholar 

  18. Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum. 1988;31(8):1007–13.

    Article  CAS  PubMed  Google Scholar 

  19. Fabbri P, et al. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4(7):449–65.

    Article  PubMed  Google Scholar 

  20. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3(3):58–68.

    Article  CAS  PubMed  Google Scholar 

  21. Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Mackay IR, Rose NR. Encyclopedia of medical immunology, vol. 3. Springer Science; Berlin, 2013.

    Google Scholar 

  23. Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007;5(12):1124–37.

    Article  PubMed  Google Scholar 

  24. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol. 1996;135(3):355–62.

    Article  CAS  PubMed  Google Scholar 

  25. Paran D, Fireman E, Elkayam O. Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. Autoimmun Rev. 2004;3(1):70–5.

    Article  PubMed  Google Scholar 

  26. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis. 2006;1:6.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Askanase A, Shum K, Mitnick H. Systemic lupus erythematosus: an overview. Soc Work Health Care. 2012;51(7):576–86.

    Article  PubMed  Google Scholar 

  28. Janssens P, et al. Lupus enteritis: from clinical findings to therapeutic management. Orphanet J Rare Dis. 2013;8:67.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tebbe B, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997;77(4):305–8.

    CAS  PubMed  Google Scholar 

  30. Callen JP, Fowler JF, Kulick KB. Serologic and clinical features of patients with discoid lupus erythematosus: relationship of antibodies to single-stranded deoxyribonucleic acid and of other antinuclear antibody subsets to clinical manifestations. J Am Acad Dermatol. 1985;13(5 Pt 1):748–55.

    Article  CAS  PubMed  Google Scholar 

  31. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

    Article  CAS  PubMed  Google Scholar 

  32. Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011;65(6):e179–93.

    Article  PubMed  Google Scholar 

  34. Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13(4):300–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tripp JM, Maibach HI. Hydroxychloroquine-induced retinopathy: a dermatologic perspective. Am J Clin Dermatol. 2006;7(3):171–5.

    Article  PubMed  Google Scholar 

  36. Leandro MJ, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673–7.

    Article  PubMed  Google Scholar 

  37. Merrill JT. Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis. 2012;70(3):172–6.

    PubMed  Google Scholar 

Dermatomyositis

  1. Bende Wald MJ, Welter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. A population based study in Olmsted County Minnesota. Arch Dermatol. 2010;146:26–30.

    Google Scholar 

  2. Mc Cann LJ, Juggin SAD, Maillard SM, et al. The Juvenile dermatomyositis. National Registry and Repository (UK and Irland) -Clinical characteristics of children within the first 5 years. Rheumatology (Oxford). 2006;45:1255–60.

    Article  CAS  Google Scholar 

  3. JOrrizzo JK, Vleugels RA. Dermatomyositis. In: Bolognia JL, Jorrizo JL, Schafter JW, editors. Dermatology. 3rd ed. Elsevierp; Netherlands, 2012. 631–91.

    Google Scholar 

  4. Nuang YL, Chm YJ, Lim MW, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan. A nation-wide, population based study. Br J Dermatol. 2009;161:854–60.

    Article  Google Scholar 

  5. Amagai M, Hashimato T, Shimizu H, et al. Asorption of pathogenic autoantibodies bythe extracellular domain of pemphigus vulgaris antigen(Dsg 3) produced in vaculovirus. J Clin Invest. 1994;94:55–7.

    Article  Google Scholar 

Scleroderma

  1. Lever WF. Histopathology of the skin. 1st ed. Philadelphia: J.B. Lippincott Co.; 1949. p. 260–4.

    Google Scholar 

  2. Le Roy EC, Black C, Fleischmajer R. Scleroderma (systemic sclerosis), classification and pathogenosis. J Rheumatol. 1988;15:202–5.

    Google Scholar 

  3. Silver RM, Medsger TA Jr, Bolster MB. Systemic sclerosis and scleroderma variants. In: Kooperman NJ, Moorland LW, editors. Arthritis and allied conditions. 15th ed. Baltimore: Lippincott, Williams-Wilkins; 2005. p. 1635–80.

    Google Scholar 

  4. Sato S. Classification of SSc and early diagnosis. Jpn J Dermatol. 2008;118:2745–9. (Japanese).

    Google Scholar 

  5. Connolly MK. Systemic sclerosis(scleroderma) and related disorders. In: Bolognia J Jr, Jorrizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Elsevier; Netherlands, 2013. p. 643–55.

    Google Scholar 

  6. Amagai M, Hashimoto T, Shimiza H, et al. Absorption of pathogenic autoantibodies by the extracellular domail of pemphigus vulgaris antigen(Dsg3)produced by vacuovirus. J Clin Invest. 1994;94:55–7.

    Article  Google Scholar 

  7. Asano Z. Detection and interpretation of autoantibodies in collagen vascular diseases Japan. J Dermatol. 2014;124:1533–8 (In Japanese).

    Google Scholar 

  8. Peterson LS, Nelson AM, Su WP, et al. The epdemiology of morphea (localized scleroderma) in Olmsted county 1960–1993. J Rheumatol. 1997;24:73–80.

    CAS  PubMed  Google Scholar 

  9. Rocken M, Ghoreschi K. Morphea and lichen sclerosus. In: Bolognia JL, Jorrizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Elsevier; Netherlands, 2013. p. 657–70.

    Google Scholar 

Lichen Sclerosus

  1. Farrell AM, Marren P, Dean D, et al. Lichen sclerosus: evidence that immunological changes occur at all levels of the skin. Br J Dermatol. 1999;140:1087–92.

    Article  CAS  PubMed  Google Scholar 

  2. Carli P, Moretti S, Spallanzani A, et al. Fibrogenic cytokines in vulvar lichen sclerosus. J Reprod Med. 1997;42:161–5.

    CAS  PubMed  Google Scholar 

  3. Terlou A, Santegoets LAM, van der Meijden WI, et al. An auto-immune phenotype in vulval lichen sclerosus and lichen planus: a Th1 response and levels of microRNA-155. J Invest Dermatol. 2012;132:658–66.

    Article  CAS  PubMed  Google Scholar 

  4. Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet. 2003;362:118–23.

    Article  CAS  PubMed  Google Scholar 

  5. Edmonds EV, Oyama N, Chan I, et al. Extracellular matrix protein 1 autoantibodies in male genital lichen sclerosus. Br J Dermatol. 2011;165:218–9.

    Article  CAS  PubMed  Google Scholar 

  6. Howard A, dean D, Cooper S, et al. Circulating basement membrane zoen antibodies are found in lichen sclerosus of the vulva. Australas J Dermatol. 2004;45:12–5.

    Google Scholar 

  7. Gambichler T, Hoxtermann S, Skrygan M, et al. Occurrence of circulating anti-bullous pemphigoid antibodies in patients with lichen sclerosus. J Eur Acad Dermatol Venereol. 2011;25:369–70.

    Article  CAS  PubMed  Google Scholar 

  8. Goolamali SK, Barnes EW, Irvine WJ, et al. Organ specific antibodies inpaients with lichen sclerosus. Br Med J. 1974;4:78–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Harrington CI, Dunsmore IR. An investigation into the incidence of auto-immune disorders in patients with lichen sclerosus et atrophicus. Br J Dermatol. 1981;104:563–6.

    Article  CAS  PubMed  Google Scholar 

  10. Meyrick-Thomas RH, Ridley CM, McGibbon DH, et al. Lichen sclerosus et atrophicus and autoimmunity: a study of 350 women. Br J Dermatol. 1988;118:41–6.

    Article  CAS  PubMed  Google Scholar 

  11. Edmonds EV, Hunt S, Hawkins D, et al. Clinical parameters in male genital lichen sclerosus: a case series of 329 patients. J Eur Acad Dermatol Venereol. 2012;26:730–7.

    Article  CAS  PubMed  Google Scholar 

  12. Marren P, Yell J, Charmock FM, et al. The association between lichen sclerosus and antigens of the HLA system. Br J Dermatol. 1995;132:197–203.

    Article  CAS  PubMed  Google Scholar 

  13. Azurdia RM, Luzzi GA, Byren I, et al. Lichen sclerosus in adult men: a study of HLA assocaitions and susceptibility to auto-immune disease. Br J Dermatol. 1999;140:79–83.

    Article  CAS  PubMed  Google Scholar 

  14. Clifton MM, Garner IB, Kohler S, et al. Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus: evidence of loss of androgen receptors in lesional epidermis. J Am Acad Dermatol. 1999;41:43–6.

    Article  CAS  PubMed  Google Scholar 

  15. Gupta S, Malhotra AK, Ajith C. Lichen sclerosus: role of occlusion of the genital skin in the pathogenesis. Indian J Dermatol Venereol Leprol. 2010;76:56–8.

    Article  PubMed  Google Scholar 

  16. Edmonds EV, Bunker CB. Nuclear magnetic resonance spectroscopy of urine in male genital lichen sclerosus. Br J Dermatol. 2010;163:1355–6.

    Article  CAS  PubMed  Google Scholar 

  17. Nelson DM, Peterson AC. Lichen sclerosus: epidemiological distribution in an equal access health care system. J Urol. 2011;185:522–5.

    Article  PubMed  Google Scholar 

  18. Goldstein AT, Marinoff SC, Christopher K, et al. Prevalence of vulvar lichen sclerosus in a general gynaecologypractice. J Reprod Med. 2005;50:477–80.

    PubMed  Google Scholar 

  19. Meyrick-Thomas RH, Ridley CM, McGibbon DH, et al. Anogenital lichen sclerosus in women. J Roy Soc Med. 1996;89:694–8.

    Google Scholar 

  20. Simpkin S, Oakley A. Clinical review of 202 patients with vulval lichen sclerosus: a possible association with psoriasis. Australas J Dermatol. 2007;48:28–31.

    Article  PubMed  Google Scholar 

  21. Smith SD, Fischer G. Childhood onset vulvar lichen sclerosus does not resolve at puberty: a prospective case series. Pediatr Dermatol. 2009;26:725–9.

    Article  PubMed  Google Scholar 

  22. Kiss A, Kiraly L, Kutasy B, et al. High incidence of balantitisxeroticaobliterans in boys with phimosis: prospective 10-year study. Pediatr Dermatol. 2005;22:305–8.

    Article  PubMed  Google Scholar 

  23. Chi CC, Kitschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions of genital lichen sclerosus (Review). Cochrane Database Syst Rev. 2011;7(12), CD008240.

    Google Scholar 

  24. Neill SM, Lewis FM, Tatnall FM, Cox N. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163:672–82.

    Article  CAS  PubMed  Google Scholar 

  25. Fischer G, Rogers M. Treatment of childhood vulvar lichen sclerosus with potent topical corticosteroid. Pediatr Dermatol. 1997;14:325–8.

    Article  Google Scholar 

  26. Cooper SM, Gao XH, Powell JJ, et al. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol. 2004;140:702–6.

    Google Scholar 

  27. Dhalman-Ghozlan K, Hedblad MA, von Krogh G. Penile lichen sclerosusetatrophicus treated with clobetasoldipropionate cream: a retrospective clinical and histopathological study. J Am Acad Dermatol. 1999;40:451–7.

    Article  Google Scholar 

  28. Virgili A, Borghi A, Toni G, et al. First randomized trial on clobetasol propionate and mometasonefuroate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br J Dermatol. 2014;171:388–96.

    Article  CAS  PubMed  Google Scholar 

  29. Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2014;71:84–91.

    Article  CAS  PubMed  Google Scholar 

  30. Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64:e99–104.

    Article  CAS  PubMed  Google Scholar 

  31. Kulkarni S, Barbagli G, Kirpekar D, et al. Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients. Eur Urol. 2009;55:945–56.

    Article  PubMed  Google Scholar 

  32. Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus. Am J Clin Dermatol. 2013;14:27–47.

    Article  PubMed  Google Scholar 

  33. Lewis FM. Lichen sclerosus. In: Lebwohl MG, editor. The treatment of skin disease. 4th ed. Elsevier; Netherlands, 2014. p. 399–401.

    Google Scholar 

  34. Wallace HJ. Lichen sclerosusetatrophicus. Trans St John’s Hosp Dermatol Soc. 1971;57:9–30.

    CAS  Google Scholar 

  35. Zaki I, Dalziel KL, Solomons FA, et al. The under-reporting of skin disease in association with squamous cell carcinoma of the vulva. Clin Exp Dermatol. 1997;21:334–7.

    Google Scholar 

  36. Derrick EK, Ridley CM, Kobza-Black A, et al. A clinical study of 23 cases of female anogenital carcinoma. Br J Dermatol. 2000;143:1217–23.

    Article  CAS  PubMed  Google Scholar 

  37. Chiesa-Vottero A, Dvoretsky PM, Hart WR. Histopathologic study of thin vulvar squamous cell carcinomas and associated cutaneous lesions: a correlative study of 48 tumors in 44 patients with analysis of adjacent vulvar intraepithelial neoplasia types and lichen sclerosus. Am J Surg Pathol. 2006;30:310–8.

    Article  PubMed  Google Scholar 

  38. Powell J, Robson A, Cranston D, et al. High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis. Br J Dermatol. 2001;145:85–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Rui Jin hospital, School of Medicine, Shanghai Jiao Tong University, 197 Rui Jin Er Road, Shanghai, China

    Jie Zheng & Meng Pan

  2. Dermatological Department, University of Pisa, Pisa, Italy

    S. Gianfaldoni

  3. Division of Dermatology, University of Florence, Florence, Italy

    A. M. D’Erme

  4. University of Rome “G. Marconi”, Rome, Italy

    T. Lotti

  5. Department of Dermatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China

    Xingqi Zhang

  6. Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, #139 Renmin Middle Road, Changsha, Hunan, 410011, China

    Peng Zhang, Jin Yuan & Qianjin Lu

  7. Wayne State University School of Medicine, Detroit, MI, USA

    Ken Hashimoto MD

  8. Wexham Park Hospital, Wexham Street, Slough, SL2 4HL, UK

    Fiona Lewis

  9. St John’s Institute of Dermatology, St Thomas Hospital, Lambeth Palace Road, London, SE1 7EH, UK

    Fiona Lewis

Authors
  1. Jie Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meng Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Gianfaldoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. M. D’Erme
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Lotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xingqi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qianjin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ken Hashimoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Fiona Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jie Zheng , T. Lotti , Xingqi Zhang , Qianjin Lu , Jie Zheng , T. Lotti , Xingqi Zhang , Qianjin Lu or Fiona Lewis .

Editor information

Editors and Affiliations

  1. Dermatology, The first affiliated Hospital China Medical University, Shenyang, China

    Xing-Hua Gao

  2. Dermatology, The first affiliated Hospital China Medical University, Shenyang, China

    Hong-Duo Chen

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Zheng, J. et al. (2017). Autoimmune Dermatoses. In: Gao, XH., Chen, HD. (eds) Practical Immunodermatology. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-0902-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-024-0902-4_13

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-024-0900-0

  • Online ISBN: 978-94-024-0902-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation